Source comparison
Thymosin Alpha-1 Cancer Adjunct: Clinical Protocol Comparison
Hepatocellular Carcinoma TACE + sorafenib 1.6mg SC twice weekly × 24 weeks +4.7 months (p=0.004) Shanghai Cancer Centre Phase III (2022) Strongest evidence base. Immune restoration in chronically suppressed liver microenvironment Non-Small Cell Lung Cancer Car
This comparison does not assign a generated winner or score.
- Hepatocellular Carcinoma
- TACE + sorafenib
- 1.6mg SC twice weekly × 24 weeks
- +4.7 months (p=0.004)
- Shanghai Cancer Centre Phase III (2022)
- Strongest evidence base. Immune restoration in chronically suppressed liver microenvironment
- Non-Small Cell Lung Cancer
- Carboplatin-paclitaxel
- 1.6mg SC twice weekly during chemo cycles
- +2.1 months (p=0.019)
- Clinical Cancer Research Phase II (2023)
- Moderate benefit. Timing must align with chemo infusion
- Melanoma (chemo-eligible)
- Dacarbazine monotherapy
- 1.6mg SC twice weekly × 16 weeks
- +2.6 months (p=0.031)
- JCO Phase II (2021)
- Niche application. No benefit if already on checkpoint inhibitors
- Gastric Adenocarcinoma
- FOLFOX chemotherapy
- 1.6mg SC twice weekly during cycles
- +1.8 months (p=0.12, NS)
- Cancer Immunology Research (2023)
- Insufficient evidence. Trial underpowered, benefit not statistically significant